To test whether a treatment that targets PD-1/PD-L1 blockade could be effective in tauopathy, we used a transgenic mouse model that expresses two mutations of the human-tau gene (K257T/P301S; double mutant, DM-hTAU) associated with Frontal-Temporal dementia31. Here, MAPT is linked to tauopathy.